MX2013013504A - Topical wash composition for use in acne patients. - Google Patents

Abstract

The present invention relates to wash compositions for topical application, stable and well tolerated and to their uses thereof as cosmetic or pharmaceutical products, said compositions being used for cleansing the skin, preferably of acne patients, without compromising the skin barrier or resulting in over-compensation of sebum production. More preferably the invention relates to a topical wash composition comprising:10 a) at least one surfactant, b) a zinc salt of gluconic acid, c) a salt or derivative of glycyrrhizic acid or of glycyrrhetinic acid.

Description

TOPICAL COMPOSITION FOR WASHING FOR USE IN PATIENTS WITH ACNE Description of the invention The present invention relates to compositions skin barrier or resulting in overcompensation of, or sebum production.

Acne is a common multifactorial pathology that attacks the skin rich in sebaceous glands (face, area of the spleen, arms and intertriginal areas). It is the most commonly occurring form of dermatosis. The five factors play a decisive role in the genetics; 2. overproduction of sebum (seborrhea); 3. androgens; of follicular keratinization bacterial and inflammatory factors. sas forms of acne, the common factor of pilosebaceous follicles. It can be particular, of acne conglobata, acne I Ref. 244907 quelbide of the nape of the neck, medicated acne, recurrent miliary acne, necrotic acne, neonatal acne, premenstrual acne, occupational acne, acne rosacea, senile acne, Solar acne and common acne.

Common acne, also known as polymorphic juvenile acne, is the most common. It comprises four stages: j- stage 1 corresponds to comedonic acne characterized by a large number of open and / or closed comedones and micrc-cysts; 0 -. 0 - stage 2, or papulopustular acne, is mild in severity 'moderate. It is characterized by the presence of comedones i abidrtos and / or closed, of microcysts, but also of pustules and red papules. It mainly affects the face and leaves few scars; 5 - . 5 - stage 3 or papulocomedonic acne, is more serious and extends to the back, chest and shoulders. It is accompanied by a large number of scars; I Stage 4, or nodulocystic acne, is accompanied by numerous scars. It exhibits nodules and also painful or voluminous crimson pustules. (in particular the product Retacnyl sold by the company Galderma) or isotretinoin (the product Roaccutane * sold by Laboratoires Roche), or else with derivatives of naphthic acid. The naphthoic acid derivatives such as, in particular, 6- [3- (1-adamantyl) -4-methoxy-phenyl] -2-naphthoic acid, which is commonly referred to as adapalene (the product I © Differine sold by the company Galderma), are widely described and recognized as active ingredients that are as effective as tretinoin for the treatment of acne. i I Some adverse events (AE, by its abbreviations in i English) appear with Rx (with prescriptions) and produce AE cutaneous side effects 27% of subjects with AE related to the application site and the. more important is I Dry skin. i j In general, anti-acne therapies can cause dry skin, which may be due to damage to the skin barrier, leading to increased water loss from the stratum corneum (TEWL: Loss of Trans-Epidermal Water). Therefore, a barrier of intact skin is essential for the proper functioning of the physical and chemical elements of the protective actions of the skin. Acne directly influences the barrier function of the skin via the inflammatory and overproduction of sebum. The production Excessive sebum leads to unbalanced skin lipids and structural alterations in the components of the clavjss barrier, such as the deficiency of fatty acids and also the ceramides which in turn leads to the skin barrier and TEWL increased can aggravate acne. Consequently dermatologists recognize the value of moisturizers and cleansers as adjuvants to prescribed treatments. G recommended skin for acne covers the Stage 2: Medicate (Rx treatment) 5 i Stage 3: Hydrate and Protect It is useful to have skin care products that improve the signs / symptoms of acne.

The present invention relates to a composition in step 1 as a product for washing. cleaning does not directly address the acne mechanism, it is considered that good care of the Daily cleansing is an important part of achieving dermatological health in patients with acne. 1 1 i j There is often a tendency among acne victims 5 to "be cleaner". Many use washes astringent, exfoliating and abrasive in an attempt to completely remove sebum and dirt. Severe cleaning is detrimental to the skin with acne, particularly when they undergo medical treatments that provide lesions to the barrier of already compromised skin. During Cleansing can stimulate the overproduction of sebum and can increase the severity of acne.

An object of the present invention is to provide a stable and well-tolerated topical dermatological / pharmaceutical washing composition which effectively cleanses the skin of patients with acne, without the acne in them. he has 0 found that the composition comprising at least: a) a surfactant, I b) a zinc salt of gluconic acid, I c) a salt or derivative of glycyrrhizic acid or glycyrrhetinic acid, 5 responds to the following needs: f Wash / clean skin, Formulation that regulates sebum, With a non-comedogenic action, j- Maintain the integrity of the skin barrier, and i- With additional action as required for the patient's acceptability: a foaming action.

To achieve the cleaning action, the present invention requires the presence of at least one surfactant. In order to confer good tolerability and no irritation, that is, maintain the integrity of the skin barrier, the man skilled in the art knows that the non-ionic surfactant are well tolerated surfactants and could be used. However, the latter do not have good foaming properties. It is known that surfactants having good foaming properties have the disadvantages of being irritant. The first problem to be solved is to find the suitable surfactants that confer to the composition, the cleaning properties as well as the good tolerability and the required foaming action.

As a solution to the problem to be solved in [the invention, the present invention provides compositions with new generations of mild anionic surfactants adapted to the skin with acne and sensitive, to provide a cleaning composition for washing soap-free foaming agent according to the invention. According to the invention, the surfactants are considered to be mild when their application results in minimal swelling, binding and irritation of the skin. Sodium lauryl sulfate is often selected as a reference example of an irritant surfactant. A mild surfactant is less irritating than sodium lauryl sulfate, but also sodium lauryl ether sulfate.

An anionic surfactant according to the invention is designated as such due to the presence of a negatively charged part. The general form of an anionic surfactant is RX "M +.

Where R is the length of the carbon chain, M is the neutralizing group (such as sodium, potassium, magnesium, zinc, ammonium, triethanolamine), X is the negatively charged species which may be any of the following: carboxylate, sulfonate, sulfate or phosphate.

I These surfactants have detergent and / or cleaning properties. The mild anionic surfactants are more specifically selected from the following list, used alone or in combination: - carboxylate derivatives, such as annihil isethionates or acyl isethionates (sodium, potassium, ammonium or magnesium salts) such as sodium cocoyl isethionate sold by i Clariant under the trade name Hostapon SCI-85G or i laur il methyl isethionate called Iselux de Innospec, amino acids and acyl amino acids such as glutamate, acyl glutamate, lauroyl glutamate called Protelan AGL 95 & Schartz, capriloyl glutamate sodium too $ sold by Zschimmer & Schartz and called Protelan AG8, sarcosinate or acyl sarcosinate such as lauroyl sarcosinate sodium called Protelan LS9011 sold by Zschimmer & Scharitz, glycinate or acyl glycinate such as cocoyl glycinate fatty acid arginate, 0 peptides, amino acid of APL of SEPPIC, lactylates' s sodium carboxylate I (plaíitapon LGC sorb de Cognis), laureth-13 carboxylate, ! - sulfate derivatives: 5-alkyl sulfates, alkyl ether sulphites, alkylamino ether; sulphates, alkylarylpolyether sulfates, sulfates of monoglycerides I such as zinc cocato sulphate sold by Zschimmer & Schartz under the trade name Zetesol ZN, I - sulfonate derivatives: 0, j alkyl sulfonates, alkylamidesulfonates, i sulfonates, α-olefinsulfonates and preferably Ci4-Ci6-fontates, preferably their sodium salt Hostapur OSB from Clariant, paraf-insulfonates, alkyl sulfosuccinates such as sodium dioctyl sulfosuccinate 5; also known under the name docusate sodium, alkyl Anionic surfactants expressed by weight of active material (AM) in relation to the total weight of the composition is between 1 and 15% AM. The active material is at the percentage of pure surfactant included in an ion. In many cases the surfactants available commercially they are sold as aqueous solutions. The amount i AM can vary in the amount of water used to dilute the pure surfactant and the grade of the raw material supplied from commercial vendors.

In a preferred embodiment, the anionic surfactant is zinc cocato sulfate, in a concentration between 0.25% and 20% expressed by weight of active material (AM) with: relation to the total weight of the composition.

Preferably, the concentration expressed by weight of? active material (AM) in relation to the total weight of the composition for zinc sulfate cocato is between 1% and 15% AM, preferably between 2% and 8%.

An expert in the art can use various commercials containing zinc cocato sulfate proposed in several dilutions. Some commercial products i Specifics propose zinc sulfate cocato in 25% solution, such as ZetesoT ZN from Zschimmer & Scharz expressed by weight of active material (AM) in relation to the total weight of the solution. Accordingly, in a preferred alternative embodiment, the amount of zinc cocato sulfate (Zetesol ZN) 1 expressed by weight in relation to the total weight of the exact between 1% and 10% of active material in relation to the total weight of the composition.

According to the invention, the composition also comprises zinc gluconate.

Zinc gluconate (also called zincum gluconium) is the zinc salt of gluconic acid. It is an ionic compound consisting of two moles of gluconate per one mbl of zinc. Zinc gluconate is a popular form; for the supply of zinc as a dietary supplement.

Gluconic acid is found naturally, and is manufactured industrially by the fermentation of glucose, typically by Aspergillus niger, but also by other fungi, for example! expensive The advantages are a lower microbiological profile, a more complete reaction, producing a product with A longer shelf life.

In a preferred embodiment, the concentration of zinc gluconate, expressed by weight relative to the total weight of the composition is between 0.1% and 1%, preferably 0.15% and 0.3%, more preferably 0.2%.

According to the invention, the composition also contains a salt or derivative of glycyrrhizic acid or acid I glycyrrhetinic.

Glycyrrhizic acid is derived from the plant I Glycyrrhiza glabra, or licorice root, which has the I reputation for providing anti-inflammatory properties and I anti-irritants. The soothing and soothing properties of licorice extracts make them interesting candidates for inclusion in treatments for sensitive skin conditions such as eczema, erythema, dermatitis i seborrheic and itching.

Glycyrrhetinic acid is a derivative of pentacyclic tritjerpenoid of the beta-amyrin type obtained from the hydrolysis of glycyrrhizic acid (alternative names: glycyrrhizin and glycyrrhizinic acid), which was obtained from licorice herb. It is used to flavor and mask the bitter taste of compounds such as aloe and quinine. It is effective in the treatment of peptic ulcer and also has expectorant (antitussive) properties. It has some additional pharmacological properties, including antiviral, antifungal, antiprotozoal, and antibacterial activities. ethic As salts and derivatives, mention may be made of the potassium salt, sodium salt, monoammonium salt, ammonium glycyrrhizate, dissociate succinate, dipotassium salt of glycyrrhizic acid (dipotassium glycyrrhizate) or acid esters, such as glycerin monoester.

Chemical structure of dipotassium glycyrrhizate In a preferred embodiment, the derivative i Glycyrrhetinic is a dipotassium glycyrrhizate concentration expressed by weight in relation to the total weight of the composition between 0.1% and 1%, preferably between 0.15% and 0.3% ', more preferably 0.25%.

Therefore, one aspect of the present invention is a composition, comprising: 'a) a surfactant, b) a zinc salt of gluconic acid, c) a salt or derivative of glycyrrhizic acid or acid I glycyrrhetinic. preferably, the composition of the invention, in an acceptable cosmetic carrier, the combination minus a mild anionic surfactant zinc uconate Dipotassium icirrizate.

Planting has the advantage of cleaning the skin, but it also helps regulate the production of sebum and soothe the skin and solve the problems described above.

'The composition is for topical application and can Be of any type as known by an art expert.

As non-limiting examples of the type of composition, the composition may be in the form of a 1 solution, a gel or an emulsion. When a form is preferred j of gel, the composition contains as a constituent additional some gelling agents, such as for example microcrystalline cellulose, sodium carboxymethyl cellulose, the carbomers "electrolyte insensitive" such as Carbopol ETD2020 ™ sold by the company Noveon, polysaccharides, non-limiting examples of which include xanthan gum or gelano gum or pectin, the family of magnesium aluminum silicate, sodium magnesium silicate, sodium magnesium fluorosilicate, magnesium and sodium silicate and tetrasodium pyrophosphate, hydroxypropylmethylcellulose, the polymer family the family of polyacrylamides, such as the mixture of acryloyl dimethyl taurate copolymer 5 sodium / isohexadecane / polysorbate 80 sold under the name . ; 600PHÁ ™ by the company Seppic, or the mixture of | amide / isoparaffin C13 -14 / laureth-7 such as, for example, sold under the name SEPIGEL 305 ™ by the company Seppic, the acrylate copolymer of sodium hydroxyethyl / acryloyl dimethyl taurate under the name SEPI OV EMT 10 by the company Seppic, and the family of modified starches such as modified potato starch under the name Structure Solanace ™, or mixtures thereof.

When an emulsion form is preferred, the composition contains, in addition to the anionic surfactant, zinc gluconate and dipotassium glycyrrhizate, at least one emulsifier and an oil phase which may be a mixture of mineral, synthetic or silicone.

More preferably, according to the invention, the composition is in the form of an aqueous, aqueous or alcoholic or alcoholic solution.

In accordance with a preferred embodiment, the composition is in the form of a solution and comprises an aqueous phase as a major constituent of the carrier. The aqueous phase can be present in an amount between 10 and 99% by weight with respect to the total weight of the composition, preferably between 50 and 95% by weight and preferably comprises water. This water can be purified water, floral water such as cornflower water, or a spring or mineral water, for example selected from Vittel water, waters from the Vichy basin, Uriage water, La Roche Posay water, Avene water or Aix les Bains water . i As indicated above, the composition of the invention requires foaming properties. The owner of ; has found that to confer good particular ion properties, the composition can be used with specific container. In such packaging, the drive i of the mechanical pump applies the conditions required to transform the formulation for liquid washing into a foam product. To produce a foam the liquid wash formulation must pass through a mixing chamber, where it mixes with the air as it passes through one or more screens. In general, when the sieve diameter decreases, the density of the foam increases. In addition, smaller vjiscosity formulations tend to mix more efficiently with the air in the air chamber and form large amounts of foam. An example of a mechanical pump is the Rexam M3- 'SIO MINI FOAMER, as sold by the company Rexam-Pulvorex-Riekéj.

In another embodiment, the pH of the invention is well controlled and is between 2 and 7 preferably between 3 and 6, more preferably around 4.

In healthy skin, the pH of the typical surface Skin is affected by a large number of factors and a key element is the pH of topically applied detergent products. The composition of the invention has a relatively low pH, which has the benefit of helping the skin to restore its natural acidity and therefore Í help control the growth of microorganisms. Surprisingly, the composition of the invention maintains the pH of the skin surface stable during the period of I use of the composition. i The invention also provides a method for I I improve and / or prevent and / or inhibit the conditions i I dermatology linked with the treatment of acne. The invention also provides a treatment process for beautify the skin or its appearance of the surface, it is applied to the skin and / or its annexes of integument. In a preferred embodiment, the treatment of the skin is for skin I with an acne tendency or to combat the appearance oily skin or hair.

Throughout this text, unless it is understood that, when they occur ! , include the upper limits and 5 similarly, unless it proportions of the different constituents of the composition are expressed as a percentage í by weight (mass / mass [m / m] or weight in weight [w / w]) of the total weight j of the composition. 0 The term "topical application" is intended to 'means application to the skin or mucous membranes.

The composition according to the invention can additionally comprise at least one of the following additives mentioned as an example, used in the composition alone or in combination: j - antioxidants such as vitamin E and its derivatives, such as DL alpha tocopherol or t acetate 'Roche tocopherol, vitamin C and its derivatives, such as ascorbyl palrrlite (Roche), butylated hydroxytoluene or sold under the name Nipanox BHT by Clariant, I butylated hydoxyanisole, acetyl cysteine, citric acid, sodium metabisulphite and / or sodium sulfite , i - vitamins such as vitamin B3 (vitamin PP) or niacinamide, 5 - calming and / or anti-irritant agents such as PPG-12 / SMDI marketed by Bertek under the trade name Polyolprepolymer-2 or its derivatives or hyaluronic acid, Polyquaternium-51, such as lipidure P B sold by Rossow, D-panthenol, aloe vera, ! - lecithins, such as phosphatidyl choline, phosphatidyl inositol, phosphatidyl ethanolamine, and - an example of available phospholipid used in the pharmaceutical industry is Phospholipon 90H which is supplied by Phospholipid GmbH. ; - cholesterol or cholesterol derivatives such as i Esters of cholesterol. - preservatives: such as chlorhexidine chloride, chlorocresol and its tyl, phenoxyethanol, sorbate sodium, diazolidinylurea, benzyl alcohol, parabens or mixtures thereof, methyl paraben sold under the name Nipagin M by Clariant, propylparaben sold under the name Nipasol by Clariant, a mixture of parabens also sold by Clar'iant under the trade name Nipastat. - acids or bases, such as citric acid, lactic acid, sodium citrate, triethanolamine, aminomethyl propanol, sodium hydroxide, diisopropanolamine, I - chelating agents such as EDTA or its salts with, for example, disodium EDTA, i - humectants such as propylene glycol, glycerin, glycol, 1-2 hexanediol or caprylyl glycol, - Wetting agents such as poloxamers and / or families of glycols and more particularly Synperonic PE / L44 and / or Synperonic PE / L62 and / or compounds such as propylene glycol, dipropylene glycol, propylene glycol dipelargonate, lauroglycol, ethoxydiglycol, docusate sodium, - Foam enhancer selected from, but not restricted to, polyethylene glycol such as, for example, PEG-75, or glyceryl monocaprylate (Imwitor 308 from Sasol), I cocamidopropi 1 hydroxysultaine (Mirataine CBS from Rhodia), sesquicaprilato from sorbitan (Antil soft SC from Evonick) ! used in the composition alone or in combination, j - ingredients that provide a foam softness selected from PEG-7 glyceryl cocoate, hydrogenated PEG 200 glycine palmitate (Antil 200 from Evonick), polypropylene terephthalate (Aristoflex PEA from Clariant), C12 alkyl lactate -13 (Cosmacol ELI of ! j Sasol) used in the composition alone or in combination, ii - perfume solubilizing agents such as hydrogenated PEG-40 castor oil, hydrogenated PEG-60 castor oil, polysorbate 80, polysorbate 20. Perfume or ingredients that provide fragrance to the composition, such as natural or essential oils, - re-greasing agents such as Lamesoft PO 65 from Gognis (coco-glucoside and glyceryl oleate), softigen 767 (PEG-6-Caprilic / Capric Glijcéridos) from Sasol.

! The additives are present in the composition of the invention in proportions ranging from 0 to 20% by weight | totajl of the composition.

The invention also relates to the use of the composition for washing the skin of acne patients both under active treatments and in long-term maintenance.

The invention relates to the use of the composition for washing the skin with acne, wherein the barrier function of the skin is intact.

The invention also relates to the use of the i of the following examples, which can not limit the scope of the present invention.

Eg emplos: Example 1: pH = 4.10 Example 4: Example 5 Example 12: Example 13: Test in use to evaluate skin barrier damage using the composition according to the invention Objective: Test in use to evaluate the cleaning performance of foaming laundering in subjects with acne under anti-acne treatment.

I Patients: 45 patients with acne from 12 to 45 years old i (78% |: 12-19 years). i Protocol: The composition for washing according · . *, .. -.

Example 1 was used twice a day, morning and night four consecutive weeks.

Patients under anti-acne treatment also used a moisturizer once a day in the morning.

The hydration of the skin was evaluated by two different methods (TEWL, skin capacitance). The measurements are i They took in the basal value and after 7, 14 and 28 days of product use.

Results: • Regarding the baseline value, the TEWL did not change icatively during 14 days of use.

· On day 28 there was a statistically significant decrease of the TEWL in relation to the 0 baseline value (p <0.05). j There was no statistically significant change in the skin capacitance, a direct measurement of the 1 of the skin, for 28 days. Numerically, the skin increased in relation to the baseline value of the study.

Conclusions: In patients with acne subjected to medical lockout, based on the TEWL and hydration measurements, the use of the composition for washing according to 1, Example 1 does not induce skin barrier damage 0 while it is cleaned.

I Example 14: Test in use for evaluating skin sebum regulation using the composition according to the invention Obj ective: Test in use to evaluate the effect of the test product on the surface sebum levels of the adult patients with mild to moderate acne, no to anti-acne treatment.

Patients: 25 adult patients (18-35 years).

Protocol: The participants used the composition according to example 1 twice a day, morning and night for six consecutive weeks together with their makeup and usual moisturizer.

The change of the usual products, or the use of any medicated product for acne during the course of the study, was not allowed. Measurements with Sebumeter (Courage-Khazaka, SM 810, Germany) were taken on the forehead (2x2 cm square) and one week after the I day 49. 5: | Results: • There was a rapid and significant reduction in sebum levels immediately after the first use of the 'product. j · Sebum levels decreased throughout the 42-day period in relation to the baseline value.

On day 49, one week after washing was stopped, the sebum levels were the same as basal proving that there is no rebound effect.

Conclusion: Composition 1 is effective in the e sebum levels of skin surface immediately after use, a critical point in evaluating the effectiveness of a cleanser, and seems to control the surface levels of sebum when used daily. After a week of follow-up there is no rebound effect. pielj in adult patients with mild to moderate acne not subjected to anti-acne treatment. j I Patients: 25 adult patients (18-35 years).

I Protocol: The participants used the composition for washing according to example 1 twice a day, morning and night for six consecutive weeks in ' Set with your makeup and usual moisturizer. I do not know allowed to change these products or use any i Product medicated for acne during the course of the study. The pH measurements were taken in triplicate in the center of the cheek using a pH meter (Courage-j Khazaka, Germany) on the 5 days 14, 28, 42 and one week after the end of the test on day 49 . pH values were maintained trial period.

J Conclusion: The use of composition 1 does not damage the skin barrier as evidenced by a stable skin surface pH during 6 weeks of use.

Example 16: Test to measure the sensitization potential of the composition according to the invention Objective: To confirm that the composition according to Example 1 does not produce allergic reactions on human skin under the maximized exposure conditions of this standard test.

Subjects: 215 healthy volunteers, aged between 18 and 65 (average 45.5 ± 11.7) years.

Protocol: During the challenge phase (3) the test materials were applied three times for low occlusion on the skin. The patches were removed of -48 hours and any skin reaction was evaluated visually on a scale of 1-5 to 48, 72 and 96 hours. The 2-week rest phase was followed by the 1-week challenge phase, when the test materials were applied back to the skin and a visual evaluation was performed at 48, 72 and 96 hours. Aqua demineata was used as a negative control, í '' Results: No irritation was observed during the induction phase.

No allergic reactions were recorded.

Conclusion: the composition according to Example 1 does not induce any allergic reaction or show any. potential for awareness.

! Example 17: Test to confirm the good 5 toleIrability of the composition according to the invention Objective: To evaluate the tolerability of washing from 0 i Protocol: The composition according to the example '1 was used twice a day, morning and night for four consecutive weeks.

The patients were under anti-acne treatment and used a moisturizer once a day on the first day. 5 morning The skin was examined by a certified dermatologist, the advice on the baseline value and on the visits? subsequent (days 7, 14, 28). Subjects were asked to report any subjective irritation (itching, tightness, burning and stinging) that they may have experienced in using the test product.

I I Results: I j · No statistically significant changes were observed in relation to baseline, in erythema, edema : or roughness by the dermatologist after 14 or 28 days of 5 use • No significant change was reported, regarding the baseline value, in the degree of burning, itching, stinging or tightness in the patients after 7, 14 or 28 days of use.

Conclusions: The data from both the dermatologist and the subjects indicate that the composition according to example 1 used in combination with a moisturizing cream (once a day) is well tolerated and non-irritating in patients with acne undergoing anti-aging treatment. acne.

Example 18: Evaluation of the comedogenicity of the composition according to the invention Objective: To evaluate the comedogenicity of a foaming face wash according to Example 1 in adults with mild lacquers *.

|I ! Patients: 40 subjects with mild acne from 18 to 35 years of age.

Protocol: The composition according to the example 1 was used twice a day for four weeks i Consecutive The comedogenicity was evaluated by acne counts (comedones, papules and open pustules and performed by an experienced clinical grader.

? Results: • After 28 days of use there was a significant improvement in the counts of acne lesions not i inflíamatorias (open and closed comedones) in comparison with the basal value.

• There were no significant changes in the counts of inflammatory acne lesions (papules and pustules) or total (inflammatory and non-inflammatory) after Conclusions: The composition according to example 1 seems to be noncomedogenic and effective in the improvement of comedone lesion counts.

Example 19: Evaluation of the cosmetic acceptability of the composition according to the invention Obj ective: Test in use to evaluate the cosmetic acceptability of the composition for lathering according to Example 1 in subjects with acne under anti-acne treatment.

Patients: 91 patients with acne from 12 to 45 years of age washing was used twice a day for four consecutive weeks, morning and night and rinsed with water. The patients were under anti-acne treatment and used a moisturizer once a day in the morning. The participants completed a questionnaire after 28 days of use.

'Results: After 28 days of use there was a significant' propprción '(P = 0.05) of the subjects who proved the foaming washing who felt that the product was easy to use, calmed their skin of the irritation of the It provided a healthy sensation to incorporate into your daily routine of the recommended washing to your family and friends .

Conclusions: Patients with acne formed a very positive opinion of the composition of example 1 according to the invention. They found it to be pleasant and easy to use, soothed their skin from the irritation of the anti-acne treatment and helped it look less greasy. The washing was cosmetically acceptable and easy to incorporate into the daily routines of skin care.

It is noted that in relation to this date, the best method known to the applicant to carry out the aforementioned invention is that which is clear from the present description of the invention.

Claims (13)

CLAIMS Having described the invention as above, the content of the following claims is claimed as property:

1. A topical composition for washing, characterized in that it comprises: a) at least one surfactant, b) a zinc salt of gluconic acid, c) a salt or derivative of glycyrrhizic acid or glycyrrhetinic acid. S

2. A composition for topical washing according to claim 1, characterized in that: a) the surfactant is at least one anionic surfactant, ! b) the zinc salt of gluconic acid is zinc gluconate, c) the salt, or derivative, of glycyrrhizic acid, or glycyrrhetinic acid, is I dipotassium glycyrrhizate. í1

3. A washing composition according to claim 2, characterized in that at least one anionic surfactant is selected from sulfates, isethionates, olefin sulphonates, taurates and amino acid derivatives. i

; 4. A composition for washing in accordance with claim 3, characterized in that at least one anionic surfactant is selected from zinc cocato sulfate, sodium cocoyl isethionate, sodium methyl lauroyl isethionate, sodium methyl cocoyl taurate, Ci4-c α-olefinsulfonates [6, preferably the sodium salt .

I 5. Composition in accordance with the claim 2 to 4, characterized in that the anionic surfactants have a concentration between 0.25% and 20% active material (AM)! in relation to the total weight of the composition, preferably between 1% to 10% of A.

6. Composition in accordance with claim | 1 or characterized in that the concentration of zinc salt gluconic acid expressed by weight relative to weight ! Total composition is between 0.1 and 1%, I i 1 Preferably between 0.15 and 0.3%.

7. Composition according to claim characterized in that the concentration of the. salt, or , of glycyrrhizic acid, or glycyrrhetinic acid, expressed by weight in relation to the total weight of composition 1 is between 0.1 and 1%, preferably between 0.15 and 0.3%. 1j

8. A topical washing composition according to claim 2, characterized in that | c ", PLe: < li j j a) between 1 and 10% zinc sulphate cocato of active material (AM) in relation to the total weight of the , I b) between 0.15 and 0.3% zinc gluconate, expressed by weight relative to the total weight of the composition, 'i c) between 0.15 and 0.3% of dipotassium glycyrrhizate expressed by weight relative to the total weight of the composition.

9. A composition according to any of the preceding claims, characterized in that it is a foaming composition.

10. Use of a composition according to the preceding claims, for the cleaning or washing the skin of patients with acne, both under active treatments and in long-term maintenance.

11. Use of the composition according to any of the preceding claims, for washing the skin with acne, wherein the function of the skin barrier remains intact. i i

12. Use of the composition according to any of the preceding claims, to regulate I The production of sebum on the skin of patients with acne. ! '

13. A method, characterized in that it is to improve administering the individual in accordance with the i